Window Therapeutics, INC.
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.0Mattributed |
|---|---|
| Latest round | strategic, $1.0M, 2025-01-01attributed |
| Founded | unknown |
| Headquarters | Dorchester, USA |
| Industry | unknown |
| Stage | series-b+ |
| Website | indow.ai |
SBIR PHASE II: ANTIBODY-DRUG CONJUGATES (ADCS) WITH HIGH DRUG-ANTIBODY RATIOS (DAR) AND MOLECULARLY TARGETED PAYLOADS -T
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | strategic | $1.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Strategic, $1.0M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $1.0M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | indow.ai, read 2026-05-07 |
| Description | self-reported | indow.ai, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.